Activation of clotting factors in cancer

Cancer Treatment and Research

Volumn 148, Issue , 2009, Pages 31-41

  Rickles, Frederick R ^a   Falanga, Anna ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; CURCUMIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TUMOR PROTEIN;

BLOOD CLOTTING; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; HUMAN; MELANOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; ENZYME ACTIVATION; ENZYMOLOGY; MOUSE; PHYSIOLOGY; THROMBOEMBOLISM; THROMBOPHILIA; TUMOR CELL LINE;

ANIMALS; BLOOD COAGULATION FACTORS; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOPLASTIN;

EID: 77953664021     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-79962-9_3     Document Type: Review

References (48)

1. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations and the risk of venous thrombosis. J Am Med Assoc 2005;293:715-722.
2. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110.
3. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400.
4. Rong Y, Post DE, Pieper RO, Burden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-1413.
5. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-1741.
6. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay D, Nawroth PP, Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96: 8663-8668.
7. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003;1:1495-1503.
8. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Natl Med 2004;10:502-509.
9. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004;104:2746-2751.
10. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 1999;78: 285-291.
11. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
12. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634.
13. Gross CP, Galusha DH, Krumholz HM. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med 2007;22:321-326.
14. von Templehoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractinated heparin on cancer survival following breast and pelvic surgery: a prospective randomized, doubleblind trial. Int J Oncol 2000;16:815-824.
15. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;21:1944-1948.
16. Altinbass M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular- weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.
17. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
18. Klerk CPW, Smorenburg SM, Otten H-M, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
19. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550.
20. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999;96:8161-8166.
21. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-716.
22. El-Sheikh A, Borgstrom P, Bhattacharjee G, Belting M, Edgington TS. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment. Cancer Res 2005;65:11109-11117.
23. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180-12185.
24. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004;12:3871-3883.
25. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Moseley CA, Alizadeh AR, Liotta DC, Snyder JP. Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Targeting 2008;16:185-197.
26. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a populationbased study. Arch Int Med 2002;162:1245-1248.
27. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100;3484-3488.
28. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. ACTA Haematol (Suppl) 2001;106:6-12.
29. Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Hemostasis and thrombosis: basic principles and clinical practice, 5th edn (Eds. R.W. Colman, J Hirsh, VJ Marder, AWClowes, and JN George). Lippincott-Raven Publishers, Philadelphia, PA, Chap 57, 2006;851-873.
30. Virchow R. Weitere Unter-suchungen Huber die Verstopgung der Lungenarterie und ihre Folgen. In: Virchow R, ed. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Meidinger Sohn: Frankfurt am Main, 1856, pp. 227-380.
31. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003;112:853-862.
32. Boccaccio C, Comoglio PM. A functional role for hemostasis in early cancer development. Cancer Res 2005;65:8579-8582.
33. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest (Supplement) 2003;124:58S-68S.
34. Contrino J, Hair GA, Schmeizl M, Rickles FR, Kreutzer DL. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol 1994;145: 1315-1322.
35. Contrino J, Hair GA, Kreutzer DL, Rickles FR. In situ expression of antigenic and functional tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215.
36. Mousa S, Patil G, Lansing L, Dier E, Kannanayakal T, Rickles, FR, Mousa SA. Modulation of cancer cell-associated procoagulant activity (PCA) with a novel, small molecule, orally active inhibitor of oxidative stress pathways. Blood 2008;112:921 (Abstr. 2666).
37. Mousa SA, Thangirala S, Dier E, Rebbaa A, Patil G, Rickles F. OT-304, a unique antitumor agent with multiple inhibitory effects on the cell cycle, cancer cell proliferation and the development of drug resistance. In: Proceed 99th Ann Mtg Amer Assoc Cancer Res. 2008; abstract #2316.
38. Bora PS, Hu Z, Tezel TH, Sohn J-H, Kang, SG, Cruz JMC, Bora NS, Garen A, Kaplan HJ. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 2003;100: 2679-2684.
39. Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952.
40. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725.
41. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VWM. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2001;60:6196-6200.
42. Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003;1:1972-1976.
43. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-347.
44. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC. Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 2005;11:8172-8179.
45. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005;11:7003-7011.
46. Fernandez PM, Chou DS, Aquilina JW, Patierno SR, Rickles FR. Unfractionated heparin (UFH) and a low molecular weight heparin (dalteparin) exhibit antiangiogenic effects using in vitro, ex vivo and in vivo angiogenesis models. Proc Am Assoc Cancer Res 2003;44:698-699.
47. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 2008;121:637-645.
48. Rickles FR. Mechanisms of cancer-induced thrombosis. J Pathophysiol Haemost Thromb 2006;35:103-111.